

In the Claims

Please amend claims 1, 19, and 154, and cancel claims 2-5, 37, 61, 63, 65, 67, 101, 103, 104, 106, 108, 111, 127, 138, 147, and 148 without prejudice or disclaimer, as follows.

1. (currently amended) A pharmaceutical composition comprising:
~~a pharmaceutical composition for administration to a subject, comprising an isolated~~
polymer of less than 50 kilodaltons composed entirely of identical repeating units and having at least two repeating charge motifs, wherein ~~the~~ each repeating charge motif is composed of a positively charged free amino moiety and a negative charge, wherein the positively charged free amino moieties of the at least two repeating charge motifs are separated by an intervening sequence of at least 32 Å, and wherein the intervening sequence is neutral, and a pharmaceutically acceptable carrier.
2. (canceled)
3. (canceled)
4. (canceled)
5. (canceled)
6. (original) The composition of claim 1, wherein the polymer is a mixed polymer.
7. (original) The composition of claim 6, wherein the mixed polymer is a peptide-nucleic acid.
8. (original) The composition of claim 1, wherein the polymer has at least 10 repeating charge motifs.

9. (original) The composition of claim 1, wherein the polymer has at least 15 repeating charge motifs.
10. (original) The composition of claim 1, wherein the polymer has at least 20 repeating charge motifs.
11. (original) The composition of claim 1, wherein the positively charged free amino moieties of the at least two repeating charge motifs are separated by a distance of at least 115 Å.
12. (original) The composition of claim 1, wherein the positively charged free amino moieties of the at least two repeating charge motifs are separated by a distance of at least 155 Å.
13. (original) The composition of claim 1, wherein the positively charged free amino moieties of the at least two repeating charge motifs are separated by a distance of at least 200 Å.
14. (original) The composition of claim 1, wherein the polymer is a synthetic polypeptide.
15. (original) The composition of claim 1, wherein the polymer is a non-native polypeptide.
16. (original) The composition of claim 1, wherein the polymer is a polypeptide having at least one modified amino acid.
17. (original) The composition of claim 1, wherein the polymer is a polypeptide having at least ten modified amino acids.

18. (original) The composition of claim 1, wherein the polymer is a polypeptide having a positive to negative charge ratio of 1:1.
19. (currently amended) A pharmaceutical composition comprising:
~~a pharmaceutical composition for administration to a subject, comprising an isolated~~
polypeptide of less than 50 kilodaltons composed entirely of identical repeating units and
having at least two repeating charge motifs, wherein ~~the~~ each repeating charge motif is
composed of a positively charged free amino moiety and a negative charge, wherein the
positively charged free amino moieties of the at least two repeating charge motifs are
separated by a distance of at least 8 amino acids, and
a pharmaceutically acceptable carrier.
- 20-146. (canceled)
147. (canceled)
148. (canceled)
149. (previously presented) The composition of claim 19, wherein the polypeptide has at least 10 repeating charge motifs.
150. (previously presented) The composition of claim 19, wherein the polypeptide has at least 15 repeating charge motifs.
151. (previously presented) The composition of claim 19, wherein the polypeptide has at least 20 repeating charge motifs.
152. (previously presented) The composition of claim 19, wherein the positive and negative charges of the repeating charge motifs are separated by at least one neutral amino acid.

153. (previously presented) The composition of claim 19, wherein the positive and negative charges of the repeating charge motifs are separated by at least five neutral amino acids.
154. (currently amended) The composition of claim 19, wherein the positive and negative charges of the repeating charge motifs are on adjacent amino acids ~~and are not separated by any neutral amino acids.~~
155. (previously presented) The composition of claim 19, wherein the positively charged free amino moieties of the at least two repeating charge motifs are separated by a distance of at least 27 amino acids.
156. (previously presented) The composition of claim 19, wherein the positively charged free amino moieties of the at least two repeating charge motifs are separated by a distance of at least 37 amino acids.
157. (previously presented) The composition of claim 19, wherein the positively charged free amino moieties of the at least two repeating charge motifs are separated by a distance of at least 47 amino acids.
158. (previously presented) The composition of claim 19, wherein the polypeptide is a synthetic polypeptide.
159. (previously presented) The composition of claim 19, wherein the polypeptide is a non-native polypeptide.
160. (previously presented) The composition of claim 19, wherein the polypeptide has at least one modified amino acid.

161. (previously presented) The composition of claim 19, wherein the polypeptide has at least ten modified amino acids.
162. (previously presented) The composition of claim 19, wherein the polypeptide has a positive to negative charge ratio of 1:1.
163. (previously presented) The composition of claim 19, wherein the amino acids separating the charged repeats are neutral amino acids.